Stockscreener 앱 받기
7.12
0.00%
0.00
시간 외 거래:
7.15
0.03
+0.42%
전일 마감가:
$7.12
열려 있는:
$6.99
하루 거래량:
1.00M
Relative Volume:
0.78
시가총액:
$554.72M
수익:
$14.79M
순이익/손실:
$-167.14M
주가수익비율:
-2.8552
EPS:
-2.4937
순현금흐름:
$-133.17M
1주 성능:
-7.65%
1개월 성능:
+21.09%
6개월 성능:
+39.06%
1년 성능:
+47.72%
1일 변동 폭
$6.80
$7.27
1주일 범위
$6.80
$7.99
52주 변동 폭
$2.41
$8.72
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
7.12 | 554.72M | 14.79M | -167.14M | -133.17M | -2.4937 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 개시 | Needham | Buy |
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Solid Biosciences (SLDB) Strengthens Financial Position with Inc - GuruFocus
Solid Biosciences Reports Positive Interim Data for SGT-003 and Advances Clinical Programs in Duchenne Muscular Dystrophy, Friedreich’s Ataxia, and CPVT - Quiver Quantitative
Solid targets Phase 3 Duchenne dosing in April after positive data - Stock Titan
Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration - Traders Union
Geopolitics Watch: What analysts say about Solid Biosciences Inc stockWeekly Trade Review & Reliable Entry Point Alerts - baoquankhu1.vn
PERCEPTIVE ADVISORS LLC Increases Stake in Solid Biosciences Inc - GuruFocus
RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan
H.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on trial data By Investing.com - Investing.com Canada
Boxer Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDB - MarketBeat
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union
Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data By Investing.com - Investing.com South Africa
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Chardan Capital Reaffirms "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Barclays Maintains Solid Biosciences (SLDB) Overweight Recommendation - MSN
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences (NASDAQ: SLDB) reports promising SGT-003 Duchenne data - Stock Titan
Perceptive invests $49.9M via warrants in Solid Biosciences (SLDB) - Stock Titan
Perceptive Life Sciences fund acquires 8.9M SLDB pre-funded warrants in Solid Biosciences (SLDB) - Stock Titan
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com India
Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union
Solid Biosciences Reports Positive Interim Data from Phase 1/2 INSPIRE DUCHENNE Trial of SGT-003, Demonstrating Robust Microdystrophin Expression and Encouraging Safety Profile - Quiver Quantitative
Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView
Gene therapy from Solid Biosciences shows muscle, heart gains in Duchenne children - Stock Titan
Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - Bitget
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Bain Capital Life Sciences (SLDB) caps Solid Biosciences stake at 9.99% after PIPE - Stock Titan
RA Capital details 9.9% Solid Biosciences (SLDB) ownership position - Stock Titan
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - MSN
Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):